New hope for Tough-to-Treat sarcoma: experimental drug combo enters trial
NCT ID NCT04807816
Summary
This study is testing whether adding a new drug called berzosertib to standard chemotherapy (gemcitabine) can better control advanced leiomyosarcoma, a type of soft-tissue cancer. It will involve 72 adults whose cancer has progressed despite prior treatments. The main goal is to see if the combination can stop the cancer from growing for at least six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
CHU Poitiers
RECRUITINGPoitiers, 86000, France
Contact Email: •••••@•••••
-
Centre Leon Berard
RECRUITINGLyon, 69008, France
Contact Email: •••••@•••••
-
IUCT Oncopôle
RECRUITINGToulouse, 31059, France
Contact Email: •••••@•••••
-
Institut Bergonié
RECRUITINGBordeaux, 33076, France
Contact Email: •••••@•••••
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
Contact Email: •••••@•••••
-
Institut de Cancérologie de l'Ouest
WITHDRAWNSaint-Herblain, 44805, France
Conditions
Explore the condition pages connected to this study.